RespireRx Pharmaceuticals Inc (fka RSPI)

[gfp927z]

Neuro, I was wondering about the 'new chemistry' that has been patented since the arrival of Dr. Street earlier in the year. Since he was at Merck's Neuro Research in the UK for 20 years, I can't help but worry that some of his ideas for these new chemical structures may have come from there. If so, isn't there the potential for some type of patent infringement with Merck? Dr. Stoll has indicated that the new CX-1763, CX-1739 series of low impacts are in this 'new chemistry' group, and it also sounds like the recent 'breakthrough' in high impact technology also came upon Dr. Street's arrival.

Beyond the potential for patent trouble with Merck, since CX-1763 and CX-1739 are from a 'new chemistry' (perhaps non-benzamides?), there could be many surprises coming toxicologically. Cortex's previous compounds that have been advanced have all been from the well characterized benzamide class (Org-24448, CX-717, and most likely CX-701, all being benzofurazans).